{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:24:58Z","timestamp":1721780698587},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.7759\/cureus.65199","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:39:25Z","timestamp":1721749165000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of the Nationwide Avastin Ban at a Tertiary Eye Care Hospital in Pakistan"],"prefix":"10.7759","author":[{"given":"Fiza","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huzaifa","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006411","article-title":"Antiangiogenic therapy for ischemic retinopathies","volume":"2","author":"Al-Latayfeh M","year":"2012","unstructured":"Al-Latayfeh M, Silva PS, Sun JK, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med. 2012, 2:a006411. 10.1101\/cshperspect.a006411","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.013","article-title":"Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome","volume":"160","author":"Dossarps D","year":"2015","unstructured":"Dossarps D, Bron AM, Koehrer P, Aho-Gl\u00e9l\u00e9 LS, Creuzot-Garcher C. Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015, 160:17-25.e1. 10.1016\/j.ajo.2015.04.013","journal-title":"Am J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181633fee","article-title":"Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection","volume":"28","author":"Mason JO 3rd","year":"2008","unstructured":"Mason JO 3rd, White MF, Feist RM, et al.. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008, 28:564-7. 10.1097\/IAE.0b013e3181633fee","journal-title":"Retina"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.09.028","article-title":"Clinical application of therapies targeting VEGF","volume":"143","author":"Yancopoulos GD","year":"2010","unstructured":"Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell. 2010, 143:13-16. 10.1016\/j.cell.2010.09.028","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha S","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013, 120:2292-9. 10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.018","article-title":"Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration","volume":"122","author":"Peden MC","year":"2015","unstructured":"Peden MC, Su\u00f1er IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015, 122:803-8. 10.1016\/j.ophtha.2014.11.018","journal-title":"Ophthalmology"},{"key":"ref7","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta LG","year":"1997","unstructured":"Presta LG, Chen H, O\u2032Connor SJ, et al.. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-9.","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study","volume":"112","author":"Michels S","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005, 112:1035-47. 10.1016\/j.ophtha.2005.02.007","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"ETDRS report number 7: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. ETDRS report number 7: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. Ophthalmology. 1991, 98:741-56. 10.1016\/S0161-6420(13)38009-9","journal-title":"Ophthalmology"},{"key":"ref10","article-title":"Development and implementation of a vitreous hemorrhage grading scale","volume":"1","author":"Lieberman RM","year":"2006","unstructured":"Lieberman RM, Gow JA, Grillone LR. Development and implementation of a vitreous hemorrhage grading scale. Retin Physician. 2006, 1:1-8.","journal-title":"Retin Physician"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020961corr1","article-title":"Prevalence of diabetes, pre-diabetes and associated risk factors: second national diabetes Survey of Pakistan (NDSP), 2016-2017","volume":"8","author":"Basit A","year":"2019","unstructured":"Basit A, Fawwad A, Qureshi H, Shera AS. Prevalence of diabetes, pre-diabetes and associated risk factors: second national diabetes Survey of Pakistan (NDSP), 2016-2017. BMJ Open. 2019, 8:e020961corr1. 10.1136\/bmjopen-2017-020961corr1","journal-title":"BMJ Open"},{"key":"ref12","article-title":"Frequency of ARMD in the local Pakistani population presenting at a tertiary care hospital","volume":"34","author":"Khaqan HA","year":"2018","unstructured":"Khaqan HA, Imtiaz U, Raza H, Imran U. Frequency of ARMD in the local Pakistani population presenting at a tertiary care hospital. PJO. 2018, 34:196-200.","journal-title":"PJO"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein R","year":"2011","unstructured":"Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011, 129:75-80. 10.1001\/archophthalmol.2010.318","journal-title":"Arch Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05174-4","article-title":"Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity","volume":"259","author":"Stone LG","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021, 259:1773-80. 10.1007\/s00417-021-05174-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S289068","article-title":"Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor","volume":"15","author":"Elfalah M","year":"2021","unstructured":"Elfalah M, AlRyalat SA, Toro MD, et al.. Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor. Clin Ophthalmol. 2021, 15:661-9. 10.2147\/OPTH.S289068","journal-title":"Clin Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy, IV: diabetic macular edema","volume":"91","author":"Klein R","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, et al.. The Wisconsin epidemiologic study of diabetic retinopathy, IV: diabetic macular edema. Ophthalmology. 1984, 91:1464-74. 10.1016\/S0161-6420(84)34102-1","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan DM","year":"2014","unstructured":"Nathan DM. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014, 37:9-16. 10.2337\/dc13-2112","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier JS","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012, 119:802-9. 10.1016\/j.ophtha.2011.12.005","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(87)33314-7","article-title":"Macular thickening and visual acuity: measurements in patients with cystoid macular edema","volume":"94","author":"Nussenblatt RB","year":"1987","unstructured":"Nussenblatt RB, Kaufman SC, Palestine AG, et al.. Macular thickening and visual acuity: measurements in patients with cystoid macular edema. Ophthalmology. 1987, 94:1134-9. 10.1016\/S0161-6420(87)33314-7","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data","volume":"34","author":"Sadda SR","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, et al.. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye (Lond). 2020, 34:480-90. 10.1038\/s41433-019-0522-z","journal-title":"Eye (Lond)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s3798","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion","volume":"2","author":"Guti\u00e9rrez JC","year":"2008","unstructured":"Guti\u00e9rrez JC, Barquet LA, Caminal JM, et al.. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol. 2008, 2:787-91. 10.2147\/opth.s3798","journal-title":"Clin Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.149674","article-title":"Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements","volume":"93","author":"Shah AR","year":"2009","unstructured":"Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol. 2009, 93:1027-32. 10.1136\/bjo.2008.149674","journal-title":"Br J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne TU","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008, 146:508-12. 10.1016\/j.ajo.2008.05.036","journal-title":"Am J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T","volume":"195","author":"Bressler NM","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Maguire MG, et al.. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol. 2018, 195:93-100. 10.1016\/j.ajo.2018.07.030","journal-title":"Am J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181b094b7","article-title":"Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage","volume":"29","author":"Huang YH","year":"2009","unstructured":"Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina. 2009, 29:1134-40. 10.1097\/IAE.0b013e3181b094b7","journal-title":"Retina"},{"key":"ref26","article-title":"Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy","volume":"1","author":"El-Batarny AM","year":"2007","unstructured":"El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol. 2007, 1:149-55.","journal-title":"Clin Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_431_17","article-title":"Using intravitreal bevacizumab (Avastin(\u00ae)) - Indian scenario","volume":"65","author":"Kumar A","year":"2017","unstructured":"Kumar A, Ravani R. Using intravitreal bevacizumab (Avastin(\u00ae)) - Indian scenario. Indian J Ophthalmol. 2017, 65:545-8. 10.4103\/ijo.IJO_431_17","journal-title":"Indian J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02489-x","article-title":"Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center","volume":"43","author":"Gonzalez-Gonzalez LA","year":"2023","unstructured":"Gonzalez-Gonzalez LA, Knickelbein JE, Doft BH, Balasubramani GK, Wisniewski S. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center. Int Ophthalmol. 2023, 43:867-76. 10.1007\/s10792-022-02489-x","journal-title":"Int Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-013-0033-1","article-title":"Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injections","volume":"2","author":"Schwartz SG","year":"2014","unstructured":"Schwartz SG, Flynn HW Jr. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injections. Curr Ophthalmol Rep. 2014, 2:1-5. 10.1007\/s40135-013-0033-1","journal-title":"Curr Ophthalmol Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ienj.2018.10.004","article-title":"Ethical prioritization of patients during disaster triage: a systematic review of current evidence","volume":"43","author":"Ghanbari V","year":"2019","unstructured":"Ghanbari V, Ardalan A, Zareiyan A, Nejati A, Hanfling D, Bagheri A. Ethical prioritization of patients during disaster triage: a systematic review of current evidence. Int Emerg Nurs. 2019, 43:126-32. 10.1016\/j.ienj.2018.10.004","journal-title":"Int Emerg Nurs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258274-impact-of-the-nationwide-avastin-ban-at-a-tertiary-eye-care-hospital-in-pakistan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:39:30Z","timestamp":1721749170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258274-impact-of-the-nationwide-avastin-ban-at-a-tertiary-eye-care-hospital-in-pakistan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.65199","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}